In
1989, INSERM unit U281(National Institute for health and Medical
Research), Urology service of the Edouard Herriot Hospital Lyon,
France and EDAP Technomed have joined their efforts and initiated
a research project in France. This project was to develop an
efficient and minimally invasive treatment for localized prostate
cancer (stages T1-T2). After ten years for development, the
Ablatherm was CE marked (European approval) and the FDA gave
approval for the United States to conduct a clinical study.
Today thousands patients have been treated
in several European centers.